Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, J. W.

Pharmacological Reviews, Vol 24, 459-508, Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics

Erythropoietin: Pharmacology, Biogenesis and Control of Production

James W. Fisher 1

1 Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana

The purpose of this review has been to describe the pharmacological actions of erythropoietin and its role in the control of erythropoiesis. It includes: a historical introduction on the discovery of the humoral control of erythropoiesis; techniques used for the assay and standardization of erythropoietin; purification and physicochemical characterization of erythropoietin; renal and extrarenal sites of production of erythropoietin; the biogenesis of erythropoietin as it pertains to the renal erythropoietic factor (erythrogenin); and a schematic model for the renal control of erythropoietin production. Pharmacological agents included in this review which are known to increase erythropoietin production are androgens, pituitary ACTH (through an action on the release of glucocorticoids from the adrenal), angiotensin, norepinephrine, 5-hydroxytryptamine (5-HT), vasopressin, prostaglandins, dibutyryl cyclic 3’, 5’-AMP and cobalt. The pharmacological agents which depress erythropoietin production are the diuretic drugs, such as mercurials, triamterene, benzydroflumethiazide, as well as chlorambudil, thio-TEPA, actinomycin D, and ionizing radiation. Other areas in the review include: the nervous system and carotid body influences on erythropoiesis; physiological and pathological inhibitors of erythropoietin and erythropoiesis; the mechanisms and sites of action of erythropoietin on the erythron; and clinical anemias and polycythemias associated with erythropoietin secretion. The recent reports on the complete isolation, purification and characterization of erythropoietin offer hope that sufficient amounts of this glycoprotein-hormone will be available in the near future for the treatment of some of the erythropoietin deficiency anemias.




This article has been cited by other articles:


Home page
HypertensionHome page
S. C. Malpas, A. S. Groom, and G. A. Head
Baroreflex Control of Heart Rate and Cardiac Hypertrophy in Angiotensin II–Induced Hypertension in Rabbits
Hypertension, June 1, 1997; 29(6): 1284 - 1290.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition